Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details 1)	3 Months Ended		9 Months Ended		1 Months Ended		3 Months Ended			9 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Feb. 29, 2012 Samsung Biosimilar Agreement [Member] USD ($)	Feb. 29, 2012 Samsung Biosimilar Agreement [Member] KRW	Sep. 30, 2014 Samsung Biosimilar Agreement [Member] USD ($)	Dec. 31, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Sep. 30, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Sep. 30, 2014 Samsung Biosimilar Agreement [Member] USD ($)	Sep. 30, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Sep. 30, 2014 Samsung Biosimilar Agreement [Member] KRW	Dec. 31, 2013 Samsung Biosimilar Agreement [Member] KRW
Schedule of Equity Method Investments [Line Items]
Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals					$ 250,000,000	280,500,000,000
Variable interest entity, qualitative or quantitative information, ownership percentage					85.00%	85.00%
Contribution from Biogen Idec to develop, manufacture and market biosimilar pharmaceuticals					45,000,000	49,500,000,000	11,000,000	23,900,000		11,000,000		11,100,000,000	25,200,000,000
Percentage of stake in entity minimum					15.00%	15.00%	12.00%			12.00%
Percentage of stake in entity maximum					49.90%	49.90%
Research and development	417,174,000	410,017,000	1,393,331,000	1,021,820,000				36,000,000
Additional milestone payment								85,000,000
Expected profit share with Samsung Bioepis								50.00%
Recognized loss	(5,394,000)	(6,170,000)	(14,932,000)	(12,270,000)			(5,400,000)		(6,200,000)	(14,900,000)	(12,300,000)
Revenue related to technical development and technology transfer services	$ 103,402,000	$ 71,016,000	$ 255,367,000	$ 174,497,000			$ 21,300,000		$ 4,300,000	$ 57,800,000	$ 18,500,000